Theravance Biopharma (TBPH) Gross Profit (2013 - 2018)

Theravance Biopharma (TBPH) has 6 years of Gross Profit data on file, last reported at $15.1 million in Q4 2018.

• On a quarterly basis, Gross Profit rose 581.94% year-over-year to $15.1 million in Q4 2018; TTM through Dec 2018 was $56.8 million, a 457.99% increase from a year earlier, with the FY2018 full-year figure at $59.7 million, up 537.61% from the prior year.
• Gross Profit for Q4 2018 stood at $15.1 million, up from $12.1 million in the prior quarter.
• Over the last five years, Gross Profit for TBPH reached as high as $22.0 million in Q2 2018 and fell as low as -$1.8 million in Q4 2014.
• Historically, Gross Profit has averaged $8.4 million across 5 years, with a median of $6.3 million in 2014.
• On a YoY basis, Gross Profit climbed as much as 53800.0% in 2014 and fell as far as 1122.29% in 2014.
• Year by year, Gross Profit stood at -$1.8 million in 2014, then jumped by 138.68% to $692000.0 in 2015, then surged by 556.94% to $4.5 million in 2016, then tumbled by 51.28% to $2.2 million in 2017, then soared by 581.94% to $15.1 million in 2018.
• Per Business Quant data, the three most recent Gross Profit figures were $15.1 million in Q4 2018, $12.1 million in Q3 2018, and $22.0 million in Q2 2018.